Hemab Therapeutics IPO raises $301.5M, stock triples and funds runway to 2029

Hemab Therapeutics completed an upsized $301.5 million IPO in May, boosting total proceeds to $346.7 million. The offering helped the company’s share price climb from $18 at debut to $53.48 by mid‑August, a three‑fold increase.

The cash influx leaves Hemab with $457.5 million on hand, which management says will support operations through 2029. The company plans to use the funds to advance its pipeline of therapies for bleeding disorders.

Since going public, Hemab has modestly grown its staff to about 80 employees. CEO Benny Sørensen described the Nasdaq listing as a natural step and a "dream come true," emphasizing the firm’s ambition to become a leading clotting biopharma.

With the quiet period over, the leadership is now free to outline its multi‑product strategy and pursue further growth opportunities in the coagulation space.